 | 
|
| |
|
Titel: Migränsjukdomens bakgrund och behandling (serie: Tema huvudvärk) 2007 nr 23 sid 1806-10
|
Referenser:
1.Campbell JK. Manifestations of migraine. Neurol Clin. 1990;8(4):841-55.
2.Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med. 2002;346(4):257-70.
3. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. 2nd edition. Cephalalgia. 2004;24 Suppl 1:1-160.
4.Blau JN. Migraine prodromes separated from the aura: complete migraine. Br Med J. 1980;281(6241):658-60.
5.Olesen J. The MacDonald Critchley Lecture. The migraine aura: clinical features and genetics. Cephalalgia. 2002;22(7):568-9.
6.Bigal ME, Lipton RB, Stewart WF. The epidemiology and impact of migraine. Curr Neurol Neurosci Rep. 2004;4(2):98-104.
7.Dahlöf C, Linde M. One-year prevalence of migraine in Sweden: a population-based study in adults. Cephalalgia. 2001;21(6):664-71.
8.Lipton RB, Stewart WF. Migraine headaches: epidemiology and comorbidity. Clin Neurosci. 1998;5(1):2-9.
9.Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646-57.
10.Rasmussen BK. Epidemiology and socio-economic impact of headache. Cephalalgia. 1999;25(2):20-3.
11.Rasmussen BK. Epidemiology of headache. Cephalalgia. 2001;21(7):774-7.
12.Russell MB, Olesen J. Increased familial risk and evidence of genetic factor in migraine. Bmj. 1995;311(7004):541-4.
13.Stewart WF, Staffa J, Lipton RB, Ottman R. Familial risk of migraine: a population-based study. Ann Neurol. 1997;41(2):166-72.
14.Svensson DA, Larsson B, Bille B, Lichtenstein P. Genetic and environmental influences on recurrent headaches in eight to nine-year-old twins. Cephalalgia. 1999;19(10):866-72.
15.Svensson DA, Larsson B, Waldenlind E, Pedersen NL. Genetic and environmental influences on expression of recurrent headache as a function of the reporting age in twins. Twin Res. 2002;5(4):277-86.
16.Svensson DA, Larsson B, Waldenlind E, Pedersen NL. Shared rearing environment in migraine: results from twins reared apart and twins reared together. Headache. 2003;43(3):235-44.
17.Burton WN, Conti DJ, Chen CY, Schultz AB, Edington DW. The economic burden of lost productivity due to migraine headache: a specific worksite analysis. J Occup Environ Med. 2002;44(6):523-9.
18.Dahlöf CG, Solomon GD. The burden of migraine to the individual sufferer: a review. Eur J Neurol. 1998;5(6):525-33.
19.Edmeads J, Mackell JA. The economic impact of migraine: an analysis of direct and indirect costs. Headache. 2002;42(6):501-9.
20.Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics. 1998;13(6):667-76.
21.Holmes WF, MacGregor EA, Dodick D. Migraine-related disability: impact and implications for sufferers' lives and clinical issues. Neurology. 2001;56(6 Suppl 1):S13-9.
22.Lipton RB, Bigal ME, Kolodner K, Stewart WF, Liberman JN, Steiner TJ. The family impact of migraine: population-based studies in the USA and UK. Cephalalgia. 2003;23(6):429-40.
23.Steiner TJ. Headache burdens and bearers. Funct Neurol. 2000;3:219-23.
24.Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia. 2003;23(7):519-27.
25.Linde M, Dahlöf C. Attitudes and burden of disease among self-considered migraineurs--a nation-wide population-based survey in Sweden. Cephalalgia. 2004;24(6):455-65.
26.Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med. 1998;4(11):1241-3.
27.Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. The ambulatory workload of office-based neurologists: implications of the National Ambulatory Medical Care Survey. Arch Neurol. 2000;57(3):418-20.
28.Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge, MA, Harvard School of Public Health on behalf of the World Health Organization and the World Bank. Global Burden of Disease and Injury Series; 1966.
29.Berg J, Stovner LJ. Cost of migraine and other headaches in Europe. Eur J Neurol. 2005 Jun;12 Suppl 1:59-62.
30.Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996;87(3):543-52.
31.Moskowitz MA, Bolay H, Dalkara T. Deciphering migraine mechanisms: clues from familial hemiplegic migraine genotypes. Ann Neurol. 2004;55(2):276-80.
32.Edvinsson L, Uddman R. Neurobiology in primary headaches. Brain Res Brain Res Rev. 2005 Jun;48(3):438-56.
33.Bahra A, Matharu MS, Buchel C, Frackowiak RS, Goadsby PJ. Brainstem activation specific to migraine headache. Lancet. 2001;357(9261):1016-7.
34.Weiller C, May A, Limmroth V, Juptner M, Kaube H, Schayck RV, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995;1(7):658-60.
35.Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33(1):48-56.
36.Martin GR, Robertson AD, MacLennan SJ, Prentice DJ, Barrett VJ, Buckingham J, et al. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol. 1997;121(2):157-64.
37.Goadsby PJ, Knight YE. Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. Cephalalgia. 1997;17(3):153-8.
38.Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350(11):1104-10.
39.Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A. 2001;98(8):4687-92.
40.Dahlöf CGH, Carlsson J, Hardebo JE, Laurell K, Lygner P-E. Huvudvärk - teori och klinik. Lund: Studentlitteratur; 2006.
41.Silberstein SD. Migraine. Lancet. 2004;363(9406):381-91.
42.Dahlöf CG, Hardebo JE. http://www.internetmedicin.se. 2007.
43.Dahlöf CGH, Linde M, Linton-Dahlöf P. Migrän - Kliniska aspekter. Lund: Studentlitteratur; 2003.
44.Dahlöf CG. Non-oral Formulations of Triptans and Their Use in Acute Migraine. Curr Pain Headache Rep. 2005 Jun;9(3):206-12.
 1806 |
 1807 |
 1808 |
 1809 |
 1810 |